French govt to boost biotech industry

21 October 2001

The French biotechnology industry association, France Biotech, says thatthe country's government has adopted its recommendations in its draft finance bill for 2002. The proposals in Plan Biotech 2002, backed jointly by France Biotech and an association of entrepreneurs, Objectif 2010, are aimed at facilitating the creation of biotechnology start-ups and accelerating the growth of existing companies. It is expected that these will become law in time for implementation next year.

The Minister of Finance, Laurent Fabius, designated biotechnology as a strategic priority for France. The new government measures will boost the growth of mature biotechnology companies as well as the initial funding of start-up firms and will encourage French, European and US investors to make large investments in France. In the longer term, France Biotech expects the measures to contribute to a renewal of the country's overall health care industry. The country's pharmaceutical sector is currently worth around 300 billion euros ($272.6 billion).

Proposal is expected to result in 500 million direct investment

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight